Abstract:Abstract Suspected cancer pathway referrals to dermatology are increasing to an extent that is overwhelming services, yet only 6% of these receive a diagnosis of melanoma or squamous cell carcinoma [Cancer Waiting Times (CWT) urgent suspected cancer referrals: referral, conversion and detection rates. Available at: https://www.cancerdata.nhs.uk/cwt_conversion_and_detection (last accessed 5 February 2024)]. There is an urgent need to identify factors that might reduce inappropriate referrals and improve this conversion rate. We analysed 100 urgent suspected skin cancer referrals from primary care, received consecutively from 1 October. Data were extracted for referring healthcare practitioner, suspected diagnosis and whether the referral was judged to meet the NICE criteria for referral of suspected skin cancers. Only 68% (n = 68) of referrals met the NICE referral criteria for urgent suspected skin cancer. In total, 97% (n = 31) of the referrals that did not meet these criteria had an eventual diagnosis of a benign lesion or nonsignificant basal cell carcinoma (BCC); one referral judged inappropriate had the clinical outcome of a BCC on the nasal tip, which would have met the NICE criteria. Overall, 17% (n = 17) of referrals came from non-general practitioners (GPs) such as physician associates or advanced nurse practitioners. These referrals were less likely to be judged to meet the NICE referral criteria than those from GPs: 41% (n = 7) of non-GP referrals were deemed appropriate vs. 73% (n = 61) of referrals from GPs. Adherence to the NICE criteria for referring suspected skin cancers to dermatology is disappointing. Crucially, less than half of referrals from non-GPs met these criteria, compared with nearly three-quarters of those from qualified GPs. This raises the case for only accepting referrals for suspected skin cancer from qualified GPs. Our evidence suggests that such a stance could potentially lead to a 5% reduction in referrals overall. It is also significant that not one of the referrals deemed to be inappropriate on paper led to an eventual diagnosis of melanoma or squamous cell carcinoma. This suggests that triaging referrals at the pre-appointment stage with the option of querying or even rejecting referrals that do not meet NICE criteria would be low risk. This could potentially reduce urgent suspected skin cancer referrals by 32%.

Challenges of diagnosing rare cancers in primary care

A Quarter Of Patients With Rarer Cancers See Gps Several Times Before Referral

Rising to the Challenge of Rare Diagnoses

Unmasking delays: bridging the gap in timely lung cancer diagnosis for UK primary care

Surgical management of rare tumors (Part 1)

Leukaemia diagnosis and primary care

An Overview of Advances in Rare Cancer Diagnosis and Treatment

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

A quantitative and qualitative analysis of patient group narratives suggests common biopsychosocial red flags of undiagnosed rare disease

Time to diagnosis for a rare disease: managing medical uncertainty. A qualitative study

Presentation of lung cancer in primary care

Hidden systems in primary care cancer detection: an embedded qualitative intervention development study

Rare tumors: a blue ocean of investigation

Rare Head and Neck Cancers and Pathological Diagnosis Challenges: A Comprehensive Literature Review

Handling Uncertainty Using Features from Pathology: Opportunities in Primary Care Data for Developing High Risk Cancer Survival Methods.

Cancer of Unknown Primary: When Imaging, Pathology, and Molecular Biology Do Not Match

The Burden of Rare Tumors in China: Results of a Population-Study

Interventions to improve timely cancer diagnosis: an integrative review

Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma

P033 Do suspected cancer pathway referrals to dermatology meet the NICE criteria for referral?

Identification of barriers to implementation of precision oncology in patients with rare cancers